Global Interventional oncology Market will reach $1.51 Billion by 2025: Meticulous Research®

Interventional oncology Market by Procedure [Embolization (TARE, TACE), Ablation (Thermal Ablation (Microwave, RF Ablation))], Product [Embolization (SIR-Spheres, TheraSpheres)], Application (Liver, Lung, Breast), and End User - Global Forecast to 2025.

Technological innovations and advancements in image guided therapies are transforming the face of clinical practice over the past few years tremendously. This has brought interventional oncology from the phase of skepticism to fully accepted and preferred treatment technique, thereby fueling the growth of the global interventional oncology market. The increasing demand for non-invasive treatment procedures, growing awareness of the benefits of the minimally invasive procedures, and faster recovery times associated with such procedures are the major aspects garnering attention and preferences for
interventional oncology in tumor treatment. Meticulous Research® in its latest publication on Interventional Oncology Market states that this market will increase at a CAGR of 7.7% from 2019 to 2025 to reach $1,506.3 million by 2025.

To provide efficient analysis, Meticulous Research® has segmented this market on the basis of Procedure {Embolization (TARE, TACE, Bland Embolization), Ablation [Thermal Ablation (Microwave, RF Ablation, Cryoablation, others) Non-thermal Ablation]}, by Product {Embolization [Radioemblic Agents (SIR-Spheres, TheraSpheres, QuiremSpheres), Non-radioactive embolic agents (Microspheres, Drug-eluting beads, Particles)] Ablation (Generators, Consumables & Accessories)}, Application (liver, lung, breast), End user (Hospitals, ambulatory care center), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa).

Geographically, North America commanded the largest share in this market followed by Europe. The major share of North America is mainly attributed to the presence of well-established healthcare facilities, such as hospitals and ambulatory surgery centers in the region, greater adoption of advanced technologies, high level of awareness and spending towards healthcare services, and greater penetration of health insurance coverage in the region.

Get FREE Sample Copy of Interventional Oncology Market Report at:

In terms of procedure, tumor embolization procedure segment accounted for the largest share in the global interventional oncology market in 2018. The large share of this segment is mainly due to better results with the procedure, specific targeting of tumor cells, and continuous advancements in embolization procedures and associated agents.

The two interventional oncology procedures — embolization and ablation — on the basis of products are segmented into tumor embolization (radioactive embolic agents/radioembolic agents and non-radioactive embolic agents) and tumor ablation (generators and consumables & accessories). Owing to being localized and directed radiation approach and favorable reimbursement scenario for radioembolization procedures, radioactive embolic agents segment commanded the largest share of global interventional oncology market in 2018.

Interventional oncology Market Key players:
The report provides competitive intelligence in terms of financials, growth strategies, product portfolios, and geographical presence for some of the key players in this market including Boston Scientific Corporation (U.S.), Cook Medical LLC (U.S.), C. R. Bard, Inc. (U.S.), Profound Medical Corp. (Canada), AngioDynamics, Inc. (U.S.), BTG plc (U.K.), Terumo Corporation (Japan), Medtronic plc (Ireland), HealthTronics, Inc. (U.S.), EDAP TMS S.A. (France), Neuwave Medical, Inc. (U.S.), Sirtex Medical Limited (Australia), Trod Medical (Belgium), Teleflex Incorporated (U.S.), Sanarus Technologies Inc. (U.S.), IMBiotechnologies Ltd. (Canada), MedWaves, Inc. (U.S.), and IceCure Medical Ltd. (Israel).

Asia-Pacific: The fastest growing regional market
North America commanded the largest share of the global interventional oncology market in 2018, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. However, Asia-Pacific will be the fastest growing regional market due to accelerated economic growth of many countries in this region and growing government focus on healthcare sector. In addition, government initiatives towards the development of healthcare facilities, rising incidence & prevalence of cancer; rising awareness towards overall health and treatment availability; growing number of middle class population and their level of disposable income; increasing health insurance penetration; and growing aging population in the region are the key factors propelling the growth of the Asia-Pacific interventional oncology market.

Browse Full Research Report with TOC at:

Table of Contents
1. Introduction
1.1. Market Ecosystem
1.2. Currency and Limitations
1.2.1. Currency
1.2.2. Limitations
1.3. Key Stakeholders

2. Research Methodology
2.1. Secondary Research
2.2. Primary Research

3. Executive Summary

4. Market insights
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers Growing Preference for Minimally invasive Treatment Procedures Increasing Incidence & Prevalence of Cancer Rising Number of Hospitals Technological Advancements in the Field of Radiology
4.2.2. Restraints Potential Risks Associated with Interventional Oncology Procedures High Cost Associated with Interventional Oncology Procedures Paucity of Skilled Healthcare Professionals
4.2.3. Opportunities Significant Growth Opportunities from Emerging Asian and Latin American Markets Introduction of Cloud-Based Medical Imaging
4.2.4. Trend Growing Integration of Image-Guided Solutions with Interventional Oncology Procedures

5. Interventional Oncology Market, by Procedure
5.1. Introduction
5.2. Tumor Embolization
5.2.1. Transarterial Radioembolization (TARE)
5.2.2. Transarterial Chemoembolization (TACE)
5.2.3. Bland Embolization
5.3. Tumor Ablation
5.3.1. Thermal Ablation Radiofrequency Ablation (RFA) Microwave Ablation (MWA) Cryoablation Other Thermal Ablation Procedures
5.3.2. Non-Thermal Ablation

6. Interventional Oncology Market, by Product
6.1. Introduction
6.2. Tumor Embolization
6.2.1. Radioembolic Agents Sir-Spheres TheraSphere QuiremSpheres
6.2.2. Non-Radioactive Embolic Agents Microspheres Particles (PVA Particles and Gelfoam Particles) Drug-Eluting Beads (DEBs)
6.3. Tumor Ablation
6.3.1. Tumor Ablation Devices/Generators
6.3.2. Consumables & Accessories

7. Interventional Oncology Market, by Application
7.1. Introduction
7.2. Liver Cancer
7.3. Lung Cancer
7.4. Breast Cancer
7.5. Prostate Cancer
7.6. Kidney Cancer
7.7. Bone Metastasis
7.8. Other Cancers

8. Interventional Oncology Market, by End User
8.1. Introduction
8.2. Hospitals
8.3. Ambulatory Surgery Centres
8.4. Research and Academia

Purchase Interventional Oncology Market Report at:

9. Interventional Oncology Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific
9.5. Rest of World
9.5.1. Latin America
9.5.2. Middle East & Africa

10. Competitive Landscape
10.1. Growth Strategies
10.2. Competitive Benchmarking
10.3. Market Share Analysis (2018)

11. Company Profiles(Business Overview, Financial Overview, Product Portfolio, Strategic Developments)
11.1. Boston Scientific Corporation
11.2. Cook Medical LLC (A Subsidiary of Cook Group)
11.3. Merit Medical Systems, Inc.
11.4. C. R. Bard, Inc. (A Subsidiary of Becton Dickinson & Company)
11.5. Profound Medical Corp.
11.6. AngioDynamics, Inc.
11.7. BTG plc
11.8. Terumo Corporation
11.9. Medtronic plc
11.10. Healthtronics, Inc.
11.11. EDAP TMS S.A.
11.12. Neuwave Medical, Inc. (Subsidiary of Ethicon Inc.)
11.13. Sirtex Medical Limited
11.14. Trod Medical
11.15. Teleflex Incorporated
11.16. IMBiotechnologies Ltd.

12. Appendix
12.1. Questionnaire
12.2. Available Customization

For Better Understanding Go Through Sample Report Before Buying (Higher Preference For Corporate email ID User):

Contact Info:
Name: Khushal
Email: Send Email
Organization: Meticulous Research®
Address: Pune, India
Phone: +91 744-7780008

Release ID: 88942750